When the MET receptor kicks in to resist targeted therapies | Oncogene
What Is MET? - MET Crusaders
Targeting un-MET needs in advanced non-small cell lung cancer - ScienceDirect
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
c-Met Proto-oncogene | Targeting Overexpression
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC - JTO Clinical and Research Reports
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
The multiple paths towards MET receptor addiction in cancer | Oncogene
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
